Peter Moldt
Partner @ Novo Ventures
Peter Moldt is a Series B investor at Novo Ventures focused on Medical and Health Care. Peter joined Novo Ventures (US) Inc. in San Francisco, California in 2012. He is a member of the Board of Directors of Allakos Inc. and Cardeas Pharma Inc. Previously, he was a board member of Cytochroma Inc., HemoFocus ApS, Neurokey A/S and Orphazyme ApS.From 2009-2012, Peter was employed with Novo A/S as a partner in Novo Ventures.In 2004, Peter co-founded Curalogic A/S, served as CEO until 2009 and took the company public in 2006. From 2000-2004, he was Chief Operating Officer of 7TM Pharma A/S, which he also co-founded. Previously, he worked for 11 years with NeuroSearch A/S, where he was responsible for all aspects of pre-clinical and clinical drug development.Peter holds a PhD in medicinal chemistry from the Royal Danish School of Pharmacy. He has also been a post doc with Yale University's department of organic chemistry.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 33%
Last updated:
For AI agents: llms.txt
Industries Peter Moldt invests in
Stages Peter Moldt invests in
Countries Peter Moldt invests in
Investment Focus
Industry
- Medical 3 (50%)
- Health Care 3 (50%)
- Biotechnology 3 (50%)
- Therapeutics 2 (33%)
- Dental 1 (17%)
Stage
- Series B 2 (33%)
- Series C 2 (33%)
- Series A 1 (17%)
- Series D 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
INBRACE
|
Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases. | $102M / Series D / Sep 08, 2021 | |
Bolt Biotherapeutics
|
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates. | $93.5M / Series C / Jul 01, 2020 | |
|
INBRACE
|
Swift Health Systems is a stealth stage medical device company developing INBRACE: a revolutionary, easy to use, wide indication, personalized orthodontic system hidden behind the teeth. Our patented self-guiding technology uses light and continuous forces to gently correct your smile with less pain and fewer doctor visits. INBRACE is FDAregistered and a catalyst for disruption in orthodontics. INBRACE increases the number of people who will seek orthodontic treatment by addressing the top concerns for patients while driving practice growth for clinicians. Our platform leverages digital treatment planning, computer modeling, and direct digital manufacturing to create a scalable, patient customized solution that delivers the standard of care across the entire range of orthodontic cases. | $45M / Series C / Oct 08, 2019 | |
|
Bolt Biotherapeutics
|
Bolt Biotherapeutics is a biotechnology company that develops a platform for cancer immunotherapy. Its platform, Boltbody, is a cancer immunotherapy that consists of immune-stimulating antibody conjugates. | $54M / Series B / Feb 07, 2019 | |
ViewPoint Therapeutics
|
ViewPoint Therapeutics is a biotechnology company dedicated to the development of treatments for diseases of protein misfolding, including cataracts. The company's crystallin stabilizers include a small molecule that is active in preclinical models of age-related cataracts via a target-based screening and optimization effort, providingphysicians with drugs to prevent or reverse protein misfolding, which is implicated in numerous common disorders of aging including cataracts, presbyopia, and neurodegenerative diseases. | $35M / Series B / Mar 05, 2018 | |
Arch Oncology
|
Formerly Known as Vasculox. Tioma is an immuno-oncology company developing anti-CD47 antibodies for the treatment of solid and hematologic cancers. The company's functionally diverse antibodies represent a new class of checkpoint inhibitors that harness both the adaptive and innate immune responses. | $86M / Series A / Aug 16, 2016 |
Co-Investors
About Novo Ventures
Novo A/S is a Danish private limited liability company wholly owned by the Novo Nordisk Foundation, and the holding company of the Novo Group and as such the majority shareholder in the publicly listed companies Novo Nordisk A/S and Novozymes A/S.Novo A/S was established in 1999 prior to the demerger of Novo NordiskA/S, where Novozymes A/S was established as a stand-alone publicly listed company. Novo's purpose and objectives are to manage the Foundation's financial assets and to ensure the Foundation sufficient dividends to cover its grant obligations for medical and scientific research etc. in Scandinavia.Novo A/S attains these objectives through:compliance with the rules and principles which are set out in the Articles of Association of the Novo Nordisk Foundation regarding exercise of the voting rights of A and B shares in Novo Nordisk A/S and Novozymes A/S, respectively, assurance that all companies in which the company has a material influence actively contribute to the development of the Novo Group and operate their business in accordance with the visions and values of the Novo Group, maintenance of a material influence on Novo Nordisk A/S and Novozymes A/S, and investment and financing business including placing of capital in companies and real property domestically and abroad.Novo’s overall investment strategy is thus to maintain ownership of Novo Nordisk’ and Novozymes’ shares at a level just above 25% and to invest dividends from these companies and other income in the life science area as well as in a broad portfolio of financial assets.Novo A/S has since 1999 established itself as an international venture capital partner in the life science area and has invested in over 50 companies in Denmark, Europe and North America. Through its financial investment activities Novo A/S seeks to spread the company’s total financial risk and at the same time to ensure a high return taking into consideration the chosen risk profile. In 2007 Novo A/S together with the Novo Nordisk Foundation established ‘Novo Seeds’. The new program (split into two sub-programs) is aimed at supporting early stage applied research in the life science area in Scandinavia. At the beginning of 2009 Novo A/S launched a new initiative, investing 'growth equity' into promising later stage/commercial stage life science companies. Novo A/S represents the interests of the Novo Nordisk Foundation through participation on the boards of the companies in the Novo Group.The companies in the Novo Group are members of a 'family of companies', independently managed, but sharing a set of common values as set out in the 'Charter for Companies in the Novo Group'. In the Charter these core values, commitments and management principles that companies in the Novo Group should live up to are described.
Novo Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Peter Moldt
Partner
|
|||
Brigid Hughes
Operations Manager
|
|||
Eric Shiozaki
Principal
|
|||
Kasim Kutay
CEO
|
|||
Peter Bisgaard
Partner & Investment Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Peter Moldt invest in?
Peter Moldt invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Peter Moldt last invest?
The most recent investment recorded for Peter Moldt closed in Sep 2021. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
